Eupraxia Pharmaceuticals Quote - EPRX

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

3.39

Bid

3.16

Offer

3.35

Volume

8,647

3.15 Day's Range 3.39

2.20 52 Week Range 4.08

Market Cap

120.76M

Previous Close

3.40

Open

3.31

Last Trade

3.15

Last Trade Time

03:12:37

Financial Volume

US$ 28,541

VWAP

3.3007

Average Volume (3m)

15,475

Shares Outstanding

35,622,553

Dividend Yield

PE Ratio

-5.87

Earnings Per Share (EPS)

-0.79

Revenue

Net Profit

-28.22M

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.eupraxiapharma.com

Headquarters

Victoria, British Columbia, Can

Founded

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was US$3.40. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of US$ 2.20 to US$ 4.08.

Eupraxia Pharmaceuticals currently has 35,622,553 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is US$121.12 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.87.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, Nov. 12, 2024...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.294117647059	3.4	3.63	3.05	13507	3.32344402	CS
4	0.02	0.593471810089	3.37	4.08	2.78	23494	3.42137838	CS
12	0.75	28.4090909091	2.64	4.08	2.2	15475	3.13873119	CS
26	0.68	25.0922509225	2.71	4.08	2.2	11895	2.94920754	CS
52	-0.16	-4.50704225352	3.55	4.08	2.2	16569	2.9173551	CS
156	-0.16	-4.50704225352	3.55	4.08	2.2	16569	2.9173551	CS
260	-0.16	-4.50704225352	3.55	4.08	2.2	16569	2.9173551	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTNTCheetah Net Supply Chain Service Inc	US$ 5.07 (171.12%)	100.77M
ZJKZJK Industrial Company Ltd	US$ 14.40 (127.13%)	14.18M
CTORCitius Oncology Inc	US$ 1.65 (61.76%)	92.34M
JANXJanux Therapeutics Inc	US$ 62.965 (56.71%)	4.5M
GWAVGreenwave Technology Solutions Inc	US$ 0.5676 (55.51%)	291.95M
REVBRevelation Biosciences Inc	US$ 0.5376 (-43.40%)	2.7M
OMEXOdyssey Marine Exploration Inc	US$ 0.47415 (-36.37%)	2.9M
GELSGelteq Ltd	US$ 2.6001 (-31.94%)	201.07k
STSSSharps Technology Inc	US$ 2.35 (-29.93%)	174.55k
SNTISenti Biosciences Inc	US$ 7.08 (-29.20%)	5.38M
GWAVGreenwave Technology Solutions Inc	US$ 0.5675 (55.48%)	291.95M
SMCISuper Micro Computer Inc	US$ 41.1873 (-1.94%)	146.15M
CTNTCheetah Net Supply Chain Service Inc	US$ 5.07 (171.12%)	100.77M
CHRSCoherus BioSciences Inc	US$ 1.98 (44.53%)	94.56M
CTORCitius Oncology Inc	US$ 1.65 (61.76%)	92.34M